Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
JMA Sets Up “Council on Medical COI” Out of Concerns Over Transparency GL
To read the full story
ORGANIZATION
- Hight Time to Hold Fundamental Debate on Drug Price Revisions: FPMAJ Director General
March 24, 2023
- Japan Umbrella Trade Organ to Beef Up Functions for Lobbying Activity
March 24, 2023
- Over 20% of All Generics under Restricted Shipments: FPMAJ
March 14, 2023
- PhRMA Unveils Proposal for FY2024 Reform, Says This Year Is “Turning Point” to Improve Access
March 10, 2023
- Labor Unions Prod MHLW to Renew Efforts to Improve Compliance with Drug Distribution Guidelines
March 3, 2023
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…